Key result
Prophylactic carvedilol fails to reduce long-term major cardiovascular events in breast cancer patients on anti-HER2 therapy.
Why the study?
The long-term cardiovascular effects of prophylactic beta-blocker cardioprotection in breast cancer patients treated with non-anthracycline anti-HER2 therapies remain unknown.
Does prophylactic carvedilol reduce long-term major adverse cardiovascular events in early-stage HER2-positive breast cancer patients on non-anthracycline anti-HER2 therapy?
Observational (n=109)
No
Does prophylactic carvedilol reduce long-term major adverse cardiovascular events in early-stage HER2-positive breast cancer patients on non-anthracycline anti-HER2 therapy?
Prophylactic carvedilol did not significantly improve long-term cardiovascular outcomes in a low-risk cohort of early-stage HER2-positive breast cancer patients, though 40% developed new modifiable cardiovascular risk factors over 7 years.
Answers are grounded in this paper and cite their sources.
Does not support routine prophylactic beta-blockade in this population; extends short-term null findings to 8-year outcomes.
Anti-HER2 therapy has improved survival in HER2-positive breast cancer patients for decades but is associated with well-established cardiotoxicity. Our prior randomized controlled trial PROTECT HER2 found no short-term benefit of prophylactic beta-blocker cardio protection (CPT) based on changes in global longitudinal strain (GLS) in a breast cancer population treated with non-anthracycline anti-HER2 therapies. The long-term cardiovascular (CV) effects of CPT remain unknown. Utilizing the PROTECT HER2 cohort with 5–10 years follow-up, we performed a post hoc analysis to assess long-term outcomes. We evaluated the incidence of major adverse cardiovascular events (MACE; defined as all-cause mortality, stroke, myocardial infarction (MI), heart failure hospitalization (HFH), and significant arrhythmias) based on CPT. We also assessed associations between CV risk factors (hypertension, hyperlipidemia, diabetes and BMI≥25 kg/m 2 ) and the occurrence of MACE. Among 109 patients the mean (SD) age was 51 (11) years, and the median (IQR) follow up was 7 (6–9) years post-RCT. Eight (7.3%) patients developed a total of 10 events, including 3 (2.8%) non-CV mortalities, 1 (0.9%) non-fatal stroke, and 6 (5.5%) arrhythmias. There were no significant associations observed between CV risk factors and MACE overall. However, 40% of patients (44/109) developed at least one new CV risk factor during follow-up. These findings demonstrate that while prophylactic CPT did not significantly impact long-term CV outcomes, a substantial proportion developed new risk factors over time, highlighting an important area for longitudinal risk monitoring and intervention.
No takes yet. Share an insight, caveat, or question.
McClelland et al. (2026) conducted an observational in HER2-positive early stage breast cancer (n=109). Prophylactic beta-blocker cardioprotection (carvedilol) vs. Standard-of-care monitoring without carvedilol was evaluated on Incidence of major adverse cardiovascular events (MACE). Prophylactic beta-blocker cardioprotection did not impact long-term cardiovascular outcomes in early-stage breast cancer patients on non-anthracycline anti-HER2 therapy, with an overall 8-year cumulative major cardiovascular events incidence of 9.7%.
Synapse has enriched 10 related papers. Consider them for comparative context: